SPO11

Across TCGA pan-cancer cohorts, SPO11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPO11 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPO11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPO11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, COAD, and UCEC are the cancer types where SPO11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.039	0.814	<.001	52	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	15	view →
UCEC	DFS	Median	All	0.959	0.621	.023	12	view →
STAD	OS	Median	All	0.222	0.729	.004	12	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
SKCM	DFS	Median	All	0.258	0.642	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPO11–LUAD (OS)

Open the LUAD breakdown →